Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TROP2 antibody-drug conjugate OBI-992

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), conjugated to a topoisomerase-1 inhibitor (TOP1i; TOP-Ii) via a hydrophilic, enzyme-cleavable linker, with potential antineoplastic activity. Upon administration of anti-TROP2 ADC OBI-992, the anti-TROP2 antibody moiety targets and binds to TROP2 expressed on tumor cells. Upon binding, internalization and linker cleavage, the TOP1i moiety is released, binds to TOP1 and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TROP2 ADC BSI-992
anti-TROP2 ADC OBI-992
anti-TROP2/TOP1i ADC OBI-992
Code name:BSI 992
BSI-992
BSI992
OBI 992
OBI-992
OBI992
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search